All News

Malar,rash,SLE, Lupus

Predictors of Remission and Low Disease Activity in SLE

d Sheila Reyes, MD

A treat-to-target strategy has been shown to improve clinical outcomes in patients with rheumatic diseases like rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis including systemic lupus erythematosus.  The goal of treatment in SLE is aimed at remission or low disease activit

Read Article
RheumNow’s expanded coverage of #ACR21 is sponsored in part by @Novartis. All content chosen by RheumNow & its Faculty.

Dr. John Cush RheumNow ( View Tweet)

Additional analysis on Phase 2 trial of Deucravacitinib (Tyk-2 inhibitor) in PsA. n=203 (dose 6mg QD v 12mg QD v Placebo) 🔹Prior-TNF vs TNF-naive: similar Significant improvement: 🔹ACR 20/50/70 & HAQ-DI 🔹TJC/SJC/enthesitis https://t.co/RV1zLpkUQe #ACR21 Abst#1820 @RheumNow

Links:

Pedro Castillo _Castillo_Pedro ( View Tweet)

Study presented by Dr. Michaela Koehm evaluated benefit of MTX in combination with ustekinmuab in PsA w/1° outcome of non-inferiority to placebo @ DAS28 @ wk 24. 🔹Randomized 173 pts 🔹52 weeks 🔹1° met (continued below) https://t.co/65ZXDjG9ur #ACR21 Abst#L12 @RheumNow https://t.co/KsBbwJuLe8

Links:

Pedro Castillo _Castillo_Pedro ( View Tweet)
Glucocorticoids (GC) in SLE on Belimumab 🔹Post-hoc, 5 phase 3 trials 🔹1° endpoint >25% pred↘️ to <7.5mg/d 🔹BEL n=1869; Placebo n=1217 🔹Baseline: 88% on GC; mean ~12.3mg/d pred 🔹Endpoint met by 17% BEL and 12% Pbo (p=0.0024) https://t.co/xp9LamlpHZ #ACR21 Abst#1283 @RheumNow

Links:

Pedro Castillo _Castillo_Pedro ( View Tweet)

#ICYMI #ACR21 Watch my interview with ⁦⁦@LatikaGupta_⁩ as she discusses the CoVAD study. @RheumNow ⁦@APLAR_org⁩ ⁦@rheumarhyme⁩ https://t.co/et0X7ltx3K

Links:

sheila RHEUMarampa ( View Tweet)

The amazing team @RheumNow and Dr.Kavanaugh are reviewing abstracts. #ACR21 https://t.co/kz8Y5mEgPN https://t.co/n0NMQ0P9uU

Links:

Nouf Al hemmadi NoufAhmedAlham2 ( View Tweet)
My Interview with Dr. Seoyoung Kim 👉🏼why/how she got into research 👉🏼her studies on CV risk w/HCQ, real world evidence CV risk w/Tofacitinib, gout T2T MACE occurrence @rheumnow #acr21 https://t.co/RjW5yfyWF6 via @YouTube

Links:

TheDaoIndex KDAO2011 ( View Tweet)

Day 1 Report from #ACR21 The first full day of Abstracts and Presentations from ACR Convergence, the 2021 Virtual meeting, was full of highly engaging sessions, quality posters and unique presentations. https://t.co/hhuGBe8dwr https://t.co/I5dCzFd9SJ

Links:

Dr. John Cush RheumNow ( View Tweet)
Dr. Dellaripa w/great talk on digital ischemia. Presents case of 25 yo F w/SLE, Class IV LN, APS, on apixaban, MMF, HCQ admitted w/AKI, ⬆️Upro & U-blood -> new HFrEF (EF 22%), tachy, & digital ischemia w/skin bx = thrombotic vasculopathy. #ACR21 Scientific Session 9T114 @RheumNow

Pedro Castillo _Castillo_Pedro ( View Tweet)

Had a blast with the @RheumNow team covering #ACR21! Eager to pour over more material over the coming weeks. What did folks do before the abstracts and videos were available online??

Pedro Castillo _Castillo_Pedro ( View Tweet)

Third Time's the Charm - COVID Vaccination While on Rituximab: Dr. Yuz Y... https://t.co/uxA00n1hxy via @YouTube Do watch my short commentary on the enhanced immuno-protection of 3rd primary #COVID dose in patients who are treated with rituximab #ACR21 @RheumNow

Links:

Md Yuzaiful Md Yusof Yuz6Yusof ( View Tweet)

Risk of retinopathy vs #lupus flares. Do watch my interview with Dr Jorge on her works on issues surrounding hydroxyxhloroquine dose #ACR21 @RheumNow https://t.co/hKsAi4dD2n

Links:

Md Yuzaiful Md Yusof Yuz6Yusof ( View Tweet)

Watch the @RheumNow #rheumatoidarthritis panel discuss some of our highlights from #ACR21! https://t.co/Q5Yps3s165

Links:

Mrinalini Dey DrMiniDey ( View Tweet)

Do watch the Autoinflammatory Faculty @RheumNow discussed a selection of data presented at #ACR21 @uptoTate @bella_mehta @DrPetryna Autoinflammatory: PAH in AOSD, VEXAS, JAKi in Still's, Role of labs in i... https://t.co/4biuKzWLBc via @YouTube

Links:

Md Yuzaiful Md Yusof Yuz6Yusof ( View Tweet)

Impromptu #TeamSparks video meeting with 2nd year fellows @KronzerMD and Dr Gregory McDermott detailing our research findings from the @MassGenBrigham Biobank (funded by @NIH_NIAMS and VERITY) @OrACORe_BWH @MayoClinic @RheumNow #ACR21 https://t.co/CQ9XDamb0E

Jeffrey Sparks MD MMSc jeffsparks ( View Tweet)

So I think the talk of #ACR21 has been ORAL Surveillance, the phase 3b/4 @US_FDA post-marketing requirement study of tofacitinib vs TNFi in CV risk pts. I've tried to capture this live through a few threads/tweets, as it happened. Catch up via this thread of threads @RheumNow

David Liew drdavidliew ( View Tweet)

Dr. Aurelie Nahm ( @AurelieRheumo) shares #ACR21 presentation findings on TNF inhibitors and radiographic progression in axSpA https://t.co/FPs43SGH5R https://t.co/MeM1Js5p4n

Links:

Dr. John Cush RheumNow ( View Tweet)
Sinusitis and Pharyngitis with Incident RA: Dr. Richard Conway discusses abstract #0564 presented at the #ACR21 annual meeting. https://t.co/rWS8VT5obl https://t.co/cHLTf9HPWe

Links:

Dr. John Cush RheumNow ( View Tweet)
RheumNow’s expanded coverage of the #ACR21 Annual meeting is sponsored in part by @bmsnews, @JanssenUS, @Novartis. All content chosen by RheumNow & its Faculty.

Dr. John Cush RheumNow ( View Tweet)

×